Abstract: The invention encompasses a method for treating hyperinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into the pancreas, thereby reducing insulin secretion from a B cell, and a method for treating hypoinsulinemic type 2 diabetes by local administration of a neurotoxin, such as a botulinum toxin, into a sympathetic ganglion, thereby reducing an inhibitory effect upon insulin secretion.
Abstract: A non-sedating anti-emetic composition in oral unit dosage form comprising from 1 to 5 mg of methotrimeprazine per unit dosage, or in unit dosage form for parenteral administration comprising from 1 to 5 mg of methotrimeprazine in each unit dosage.
Type:
Grant
Filed:
December 2, 1997
Date of Patent:
December 12, 2000
Assignee:
Link Pharmaceuticals Limited
Inventors:
Philip Malcolm Hallwood, Grahame David Barkby
Abstract: A hepatic disturbance improver which reduces fat in hepatocytes which includes an oligosaccharide of formula (1), (2) or (3), obtainable by hydrolyzing porphyran contained in seaweed of the genus Porphyra. The hepatic disturbance improver is advantageous, in that it reduces fat in hepatocytes without causing side effects.